

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Review Proposal Project

NICE Technology Appraisal No.369; Ciclosporin for treating dry eye disease which has not improved after treatment with artificial tears

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company/sponsor</u></p> <ul style="list-style-type: none"> • Santen (Ciclosporin Ikervis) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Action for Blind People • Eyecare Trust • Fight for Sight • Macular Society • Muslim Council of Britain • National Federation of the Blind of the UK • OBAC (Organisation of Blind African Caribbeans) • Royal National Institute of Blind People (RNIB) • SeeAbility • Sense • South Asian Health Foundation • Specialised Healthcare Alliance • Thomas Pocklington Trust <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Optometrists • British and Irish Orthoptic Society • British Geriatrics Society • British Ophthalmic Anaesthesia Society (BOAS) • College of Optometrists • Optical Confederation • Oxford Eye Foundation • Royal College of General Practitioners • Royal College of Nursing • Royal College of Ophthalmologists • Royal College of Pathologists • Royal Pharmaceutical Society • Royal College of Physicians • Royal Society of Medicine 	<p><u>General commentators</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Wales Council for the Blind • Welsh Health Specialised Services Committee <p><u>Comparators</u></p> <ul style="list-style-type: none"> • Allergan (carmellose sodium, fluorometholone, polyvinyl alcohol, prednisolone) • Aspire Pharma Ltd (dexamethasone, sodium cromoglicate) • Bausch & Lomb U.K Limited (prednisolone, dexamethasone, hypromellose, sodium cromoglicate) • FDC International (hypromellose, sodium cromoglicate) • Logixx Pharma Solutions Ltd (sodium hyaluronate) • Martindale (hypromellose)

<ul style="list-style-type: none"> • UK Clinical Pharmacy Association <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS Darlington CCG • NHS England • NHS Harrogate and Rural District CCG • Welsh Government 	<ul style="list-style-type: none"> • Novartis (dexamethasone, hypromellose) • Rayner Pharmaceuticals Limited (acetylcysteine, dexamethasone, sodium cromoglicate) • Reckitt Benckiser Healthcare (UK) Ltd (sodium cromoglicate) • RPH Pharmaceuticals AB (prednisolone) • Sanofi (dexamethasone, sodium cromoglicate) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Eyes and Vision Group • Eye Hope • Institute of Ophthalmology, University College London • MRC Clinical Trials Unit • National Eye Research Centre • National Institute for Health Research <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales
---	--

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

MTA Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to prepare a submission dossier, can respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non- company consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, and the British National Formulary).

All non-company organisations can nominate clinical or patient experts to present their personal views to the Appraisal Committee.